T cell vaccine AlloStim - Immunovative Therapies
Alternative Names: AlloStim; AlloStim-7; AlloStim-8; AlloStim-9; Bioengineered allogeneic immune cells (AlloStim); InSituStim; InSituVax; Intentionally mis-matched, allogeneic Th1 memory Cells (AlloStim) conjugated With CD3/CD28-coated microbeads; Mis-matched immune cell therapy (AlloStim) - Immunovative Therapies; Personalized anti-tumour vaccine - Immunovative Therapies; StimVax®Latest Information Update: 24 Apr 2023
At a glance
- Originator Immunovative Therapies
- Class Antineoplastics; Cancer vaccines; Immunotherapies; T lymphocyte cell therapies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Solid tumours; Viral infections
- No development reported Haematological malignancies
Most Recent Events
- 01 Apr 2023 Immunovative Therapies and Mirror Biologics complete the phase I/II ALLOPRIME trial in Viral infections (Prevention, In the elderly) in USA (Intradermal) (NCT04441047)
- 02 Sep 2021 Immunovative Therapies plans the phase II/III ALIVE trial in Liver cancer (First-line therapy, Late-stage disease) in Malaysia and Thailand (Intradermal or IV) (NCT05033522)
- 29 Jun 2021 Immunovative Therapies and Mirror Biologics initiates phase IIb STIMVAX trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (NCT04444622)